Chardan analyst Keay Nakae raised the firm’s price target on Monopar Therapeutics (MNPR) to $85 from $60 and keeps a Buy rating on the shares. In a letter to the editor published in The Journal of Hepatology, a new analysis of data showed that ALXN1840 rapidly improves copper balance in Wilson disease patients, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler
- Monopar Therapeutics Announces Underwriting Agreement for Stock Sale
- Positive Outlook for Monopar Therapeutics’ ALXN1840 Amid New Copper Balance Findings
- Monopar Therapeutics price target raised to $104 from $87 at BTIG
- Monopar jumps after doctor letter in Journal of Hepatology